Ready to go slide decks that Chapter Leaders can use for their Spring or Fall Learning Series. Once a chapter has presented a slide deck, they may not present it again. To obtain the actual slide deck, contact Mariel.

2020

Recommending Exercise in those with Obesity and Cardiovascular Risk Factors (1 CE)

Learning Objectives

  • Review CV risk factors, their relationship, association and prevalence in persons with obesity.
  • Discuss ASCVD risk calculators and demonstrate how to calculate 10-year and lifetime ASCVD risk.
  • List the steps in performing a comprehensive  cardiovascular physical assessment to screen for safety in starting an exercise program.
  • Describe best practices in exercise counseling and prescription in persons with obesity.

2019

Peripheral Arterial Disease: Risk Factors, Screening & Treatment (1 CE)

Learning Objectives

  • Outline the risk factors associated with PAD.
  • Describe the clinical presentation of patients with PAD.
  • List the steps to perform an Ankle Brachial Index (ABI) to screen for PAD.
  • Discuss common treatments for PAD including a supervised exercise training (SET) program for patients with claudication.

National Guidelines for the Primary Prevention of CVD: Integrating Hypertension, Cholesterol, Diabetes, and Lifestyle Guidelines into Practice (1.5 CE)

Learning Objectives

  • Cite and locate national guidelines related to CVD Risk Reduction
  • Using a case study approach, apply current CVD prevention and risk reduction guidelines to patient care planning.
  • Explain how CV risk assessment tools and patient-centered approaches can help to individualize risk factor management.
  • Describe how to identify and manage CV risk factors according to current guideline recommendations.

Diabetes and the CV Nurse: A Stepwise Approach to Management (1.0 CE, 0.6 Pharma)

Learning Objectives

  • Describe the association between diabetes and cardiovascular disease (CVD) and Chronic Kidney Disease (CKD).
  • Review ADA standards of care and CVD and CKD risk reduction.
  • Summarize clinical trial data supporting the use of antidiabetic therapy to improve CVD and CKD outcomes.
  • Explain a multidisciplinary, team-based approach to management of the patient with Type 2 Diabetes and the role of the CV clinician.

2018

Anti-hyperglycemic therapies: Improving CVD outcomes and hemoglobin A1c (1 CE)

Learning Objectives

  • Describe the new challenge for cardiology in prescribing medications to manage diabetes as well as CVD
  • Review recent clinical trials of anti-hyperglycemic therapies, CV out comes
  • Discuss appropriate anti-hyperglycemic therapy selection, dose and potential side effects with new therapies
    Review Case Studies as examples

Hypertension Guideline: Emphasis on Risk (1 CE)

Learning Objectives

  • Review the new  definition of hypertension and the categories of blood pressure in adults according to the new (2017) hypertension guidelines.
  • Describe the association between high blood pressure and cardiovascular disease risk.
  • List treatment strategies for hypertension according to patients level and risk, co-morbidities, race/ethnicity and age.

Lipid Management: Incorporating Recent Data into Clinical Practice (1 CE)

Learning Objectives

  • Review current treatment guidelines for the management of dyslipidemia
  • Analyze recent clinical outcomes trials of PCSK9 inhibitor therapies in patients with ASCVD, Familial Hyperlipidemia and Diabetes
  • Discuss the relative value of PCSK9 inhibitor therapy considering costs and outcomes
  • Review best practice strategies to insure patients have access to needed CVD therapies

Screening for Non-Valvular Atrial Fibrillation: Identifying the Undiagnosed Patient (1 CE)

Learning Objectives

  • Review prevalence and common risk factors associated with non-valvular atrial fibrillation (NVAF).
  • Describe typical signs and symptoms of NVAF and how to assess for them during a clinical encounter.
  • Discuss the importance of pulse taking and follow up ECG to screen high risk patients for NVAF.
  • Using case examples, illustrate how to initiate NVAF treatment, provide follow-up and collaboration across the continuum of care to ensure optimal patient outcomes.

Women’s Cardiovascular Care Across the Life Course – Promoting Prevention During Pregnancy and the Postpartum and Childbearing Years (1 CE)

Learning Objectives

  • Identify three pregnancy complications associated with future cardiovascular or cardiometabolic risk
  • Identify women who are at increased risk for developing these pregnancy-related complications
  • Describe the cardiovascular or cardiometabolic risk associated with these pregnancy-related complications
  • Describe clinical guidelines and recommendations for postpartum follow up and risk reduction in women with histories of these pregnancy-related complications
  • Apply evidence-based interventions to promote healthy eating, physical activity, and breastfeeding during the postpartum and childbearing years

2017

Antiplatelet Therapy Post Acute Coronary Syndrome: Choosing the Right Therapy for the Right Duration (1.0 CE, 0.7 Pharm)

Learning Objectives

  • List guideline-recommended antiplatelet therapies and indications for their use in the post-ACS patient.
  • Identify the most appropriate choice and duration of antiplatelet therapy in selected case studies.
  • Outline strategies to improve patient understanding and adherence to long-term antiplatelet therapies.

Heart Failure Guideline Update: Medications, Diagnosis and Co-Morbidities (1.0 CE, 0.5 Pharm)  

Learning Objectives

  • Understand the recommendations of pharmacotherapies from the 2016 heart failure guideline update
  • Identify the newest recommendations for initial and serial testing using biomarkers in patients with heart failure
  • Change practice based on new information for patients with heart failure with preserved ejection fraction (HFpEF)           
  • Recognize guideline supported strategies for managing comorbidities in patients with HF, including hypertension, anemia and sleep apnea

Making the Link: Cardiometabolic Risk, Diabetes and Cardiovascular Disease (1.0 CE)

Learning Objectives

  • Describe the relationship between cardiometabolic risk factors, diabetes and cardiovascular disease (CVD)
  • Outline a cardiometabolic risk reduction plan for patients at risk for diabetes and cardiovascular disease
  • Describe how accepted behavior change strategies can increase the rate of lifestyle and pharmacologic treatment adherence

Preventing and Managing VTE: Matching Patient Need to Optimal Therapy (1.0 CE, 0.5 Pharm)

Learning Objectives

  • Identify prevalence rates of venous thromboembolism (VTE), including rates for morbidity and mortality
  • Define professional guidelines for assessing risk in patients with VTE and discuss recommendations for patient management
  • Describe methods and tools for ensuring effective communication with patients and caregivers as a means of improving adherence and self-care in patients with VTE

Strategies for Managing Dyslipidemia Patients with Residual CVD Risk  (1.0 CE, 0.8 Pharm)      

Learning Objectives

  • Outline secondary prevention strategies in CVD patients with residual risk despite taking the maximum tolerated dose of statin therapy
  • Describe the clinical steps taken to identify statin intolerance (statin-associated adverse effects)
  • Differentiate between the indications for statins, PCSK9 inhibitors, and other LDL-lowering therapies

2016

Diabetes and Cardiovascular Disease (CVD): Managing Patients with High Risk and Co-Morbid Conditions (1.0 CE, 0.5 Pharm)

Learning Objectives

  • Summarize the treatment recommendations for patients with diabetes to reduce their risk of cardiovascular disease
  • Describe the relationship between acute coronary syndrome (ACS) and hyperglycemia in patients with diabetes mellitus
  • Describe how using shared decision-making with a complex patient can increase the rate of treatment adherence

Strategies for Managing Dyslipidemia Patients with Residual CVD Risk (1.0 CE, 0.8 Pharm)        

Learning Objectives

  • Outline secondary prevention strategies in CVD patients with residual risk despite taking the maximum tolerated dose of statin therapy.
  • Describe the clinical steps taken to identify statin intolerance
  • Differentiate between the indications for statins, PCSK9 inhibitors and other LDL-lowering therapies
  • Identify the potential barriers to treatment adherence for patients requiring LDL-lowering therapies and solutions to address the barriers.

2015

The Secondary Prevention Cocktail: The Key Ingredients (1.0 CE, 0.5 Pharm)

Learning Objectives

  • Review the secondary prevention guidelines for the post-ACS patient.
    Describe best practice recommendations for navigating the challenging hospital to home transition for the ACS patient
  • List the specific strategies that have proven efficacy for patients at risk for non-adherence.

2014

Heart Healthy Lifestyle Counseling: A Focus on the Female Patient (1.0 CE)

Learning Objectives

  • Identify two pregnancy complications associated with future CVD risk
  • Describe the integration of brief dietary counseling into a clinical visit
  • Apply evidence-based interventions to promote physical activity and healthy eating including the PCNA Heart Healthy Toolbox.